Which targeted therapies should we be more cautious of giving after recent immunotherapy in NSCLC?

In general, one should be cautious.

Phenomenon of increased toxicity with immune checkpoint inhibitors (ICIs) plus targeted therapies such as EGFR TKI (pneumonitis, hepatotoxicity or dermatologic toxicity), ALK TKIs (mostly hepatotoxicity) or BRAF inhibitors (hepatotoxicity, dermatologic) were obser...